Drugs / GSK4024484C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06171113 | Dec 2023 → Jun 2026 | Plasmodium falciparum malaria | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4024484C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06171113 ↗ |
| Route | Oral | “Doses administrated orally with 240 mL of water.” NCT06171113 ↗ |